Surufatinib Combined With Toripalimab in Recurrent or Metastatic Nasopharyngeal Carcinoma
Status:
Not yet recruiting
Trial end date:
2023-08-01
Target enrollment:
Participant gender:
Summary
A prospective, single-arm,mutil-center study to assess the efficacy and safety of Surufatinib
combined with Toripalimab in Recurrent or Metastatic Nasopharyngeal Carcinoma.